Table 1.
Characteristic | Patient
|
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
Age (years) | 57 | 65 | 37 | 39 | 47 | 71 | 50 | 62 | 78 | 79 | 59 | 69 | 51 | 58 |
Race | White | White | White | Black | White | White | Hispanic | Black | White | White | Black | White | White | White |
Gender | Female | Male | Female | Female | Male | Male | Male | Female | Male | Female | Male | Male | Male | Female |
ANCA by IIF | P-ANCA | P-ANCA | P-ANCA | C-ANCA | P-ANCA | P-ANCA | C-ANCA | NA | C-ANCA | Atypical | C-ANCA | P-ANCA | P-ANCA | C-ANCA |
ANCA specificity by ELISA | MPO | NA | MPO | PR3 | MPO | MPO | PR3 | PR3/MPO | NA | Neg | MPO | NA | NA | PR3 |
Extrarenal manifestations of vasculitis | Hemoptysis | None | None | Panuveitis | None | None | Pulmonary nodules | None | None | None | None | Hemorrhagic duodenitis and GI bleeding | Sinusitis and epistaxis | Venulitis of liver |
Urine protein (g/day) | 2 + on UA | 5.8 | 5.5 | 6.8 | 14 | 6.6 | 0.8 | 16 | Anuria | 3 + on UA | 3.5 | 1.9 | 5.8 | 5 |
Serum albumin (g/dl) | 3.5 | 3 | 2.9 | 2.3 | 2.3 | 3.4 | 2.5 | 2.4 | 2.6 | 1.4 | 2.8 | 2.2 | 2.9 | 1.4 |
Serum creatinine (mg/dl): | 2.5 | 2.2 | 3.5 | 1.3 | 8.6 | 3 | 0.9 | 4.1 | 4 (on HD) | 8.9 | 6 | 5.4 | 8.7 | 3.1 |
Treatment | IV CY/PRED then MMF | PRED/PO CY for 6 mo | M-PRED/PRED for 2.3 yrs/ IV CY for 6 mo | PRED/PO CY | PRED/IV CY for 2 mo | PRED/ PO CY for 1 yr | Azathioprine for 1 yr before Bx; PRED/PO CY for 1 yr | M-PRED then PRED/IV CY for 3 mo | PRED/IV CY for 2 mo | None | PRED/IV CY | M-PRED then PRED/PO CY/ PLX | NA | PRED/ IV then PO CY for 6 mo |
Length of follow-up (months) | 38 | 101 | 28 | 66 | 2 | 46 | 12 | 3 | 4 | 0.25 | 4 | 1 | 3 | 8 |
Follow-up creatinine | ESRD Died | 1.8 | 0.9 | 2.1 | ESRD Died | 2.8 | 0.8 | ESRD | 2.1 | Died | ESRD | 3.5 Died | ESRD Died | 0.8 |
Follow-up proteinuria (g/day) | ESRD | Neg | 0.770 | 4.2 | ESRD | 0.817 | Neg | ESRD | 0.701 | ESRD | 1.1 | ESRD | 1.2 |
ANCA, antineutrophil cytoplasmic antibody; Bx, biopsy; CY, cyclophosphamide; ELISA, enzyme-linked immunosorbent assay; HD, hemodialysis; IIF, indirect immunofluorescence; MMF, mycophenolate mofetil; MPO, myeloperoxidase; M-PRED, methyl-prednisolone; neg, negative; NA, not available; PLX, plasmapheresis; PO, oral; PR3, proteinase 3; PRED, prednisone; UA, urinalysis.